600+ overseas business delegates to engage with Indian pharma companies at iPHEX 2026

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is targeting approximately $1.4 billion in export business opportunities for Indian pharmaceutical companies through iPHEX 2026, as the industry looks to expand its presence across global markets and build new international customer relationships.

The focus comes as India’s pharmaceutical exports recorded approximately 6.8% growth during the first quarter of FY27 over the corresponding period of FY26.

The 12th edition of iPHEX, to be organised by Pharmexcil with the support of the Department of Commerce, Ministry of Commerce and Industry, Government of India, will be held from 7–9 September at Bharat Mandapam, New Delhi.

The three-day exhibition and conference will bring together more than 800+ exhibitors, over 600 overseas companies and around 30,000 business visitors, including manufacturers, exporters, buyers, distributors and procurement agencies.

With Indian pharmaceutical products reaching more than 150 countries, iPHEX 2026 will focus on connecting Indian companies with buyers across markets and converting these interactions into export opportunities.

Structured buyer–seller meetings will enable Indian manufacturers and exporters to engage directly with international companies around product sourcing, supply partnerships, contract manufacturing and other forms of commercial engagement.

The Q1 performance also comes against a complex global trade environment, reinforcing the importance of expanding India’s pharmaceutical presence across markets and product categories. These trends will form an important context for iPHEX 2026, where Indian companies will showcase capabilities across formulations, APIs, biologicals, vaccines, biosimilars, contract manufacturing and medical devices.

With Indian pharmaceutical products reaching more than 150 countries, market diversification will remain central to the discussions at iPHEX 2026. 

The exhibition will showcase India’s capabilities across generics, active pharmaceutical ingredients (APIs), finished formulations, biosimilars, vaccines, contract manufacturing and medical devices. Discussions will also cover sourcing partnerships, contract manufacturing and technology transfer, reflecting the widening scope of India’s pharmaceutical engagement with global markets.

Namit Joshi, Chairman, Pharmexcil, said, “The growth in pharmaceutical exports reflects the strength of Indian companies across products and markets. The opportunity now is to build on this base by expanding our engagement with international customers and identifying areas where Indian capabilities can meet demand across geographies. iPHEX 2026 is designed to facilitate that engagement and create opportunities for Indian companies to develop business relationships with overseas customers.”

Bhavin Mehta, Vice Chairman, Pharmexcil, said, “India already has significant manufacturing capabilities across formulations, APIs, vaccines, biosimilars and other pharmaceutical segments. The next opportunity is to connect these capabilities with demand emerging across different international markets.”

Raja Bhanu, Director General, Pharmexcil, said, “We are placing business engagement at the centre of iPHEX 2026. The buyer–seller meetings are being structured to enable focused discussions around sourcing requirements, products and potential partnerships.”

Nipun Jain, Chairman, iPHEX, said, “Global pharma business is built as much on trust as it is on capability. iPHEX brings both sides of that equation together Indian companies ready to expand and international buyers looking for credible partners.”